Genscript

Company Overview

Founded in 2002, GenScript manufactures and markets genomic and proteomic tools for the life science industry. The main business areas include Life science services and products, Biologics development services, Industrial synthetic biology products, and Cell therapy.

The subsidiary of GenScript group, Bestzyme Biotech Corporation (“Bestzyme”), is engaged in the synthetic biology business. Life science research services include DNA synthesis, genetic analysis and engineering services, recombinant protein production, peptide synthesis and customized antibody production, and biochemical reagents and research kits.

The DNA synthesis market is important to GenScript, and it maintains a leading position in terms of market share. GenScript has also developed several other businesses related to DNA synthesis, including DNA-sequencing services for confirming the fidelity of the sequence for DNA synthesis constructs and the production of downstream proteins from the synthesized genes.

GenScript is leveraging its capabilities to produce downstream synthetic biology products, including industrial enzymes. This business is a key growth strategy for the company, as it is complementary to its legacy business of developing and synthesizing new genes. Industrial enzymes launched as part of this effort include alpha-amylase, glucose oxidase, fungal alpha-amylase, and prolyl endopeptidase. Fungal alpha-amylase is a key enzyme for producing maltose syrup and for use in steamed bread processing. Prolyl endopeptidase is used as a beer clarificant to replace the traditional chemical clarifying agent.

Financial Highlights (FY 2023)

Company's Business Segments

• Life-science services and products : This  segment provides a broad range of offerings, such as customised DNA synthesis, oligo nucleotide synthesis, protein production, peptide synthesis, catalog equipment, antibody development, and consumables.
• Biologics development services : This segment offers an integrated end-to-end service offerings to enhance biologics development and manufacturing for biotech and biopharma partners.
• Industrial synthetic biology products : This segment helps in developing industrial enzyme through non-pathogenic microbial strains built using genetic engineering.
• Cell therapy : This segment discovers and develops advanced CAR-T therapies for the treatment of liquid and solid tumors.